A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
Clinical trial NCT01134640 · COMPLETED
Trial details
- NCT number
- NCT01134640
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2008-01-01
- Primary completion
- 2010-11-01
- Enrollment
- 286
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.